BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-24. [PMID: 33894145 DOI: 10.1016/S0140-6736(20)32511-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Anand SK, Caputo M, Xia Y, Andersson E, Cansby E, Kumari S, Henricsson M, Porosk R, Keuenhof KS, Höög JL, Nair S, Marschall H, Blüher M, Mahlapuu M. Inhibition of MAP4K4 Signaling Initiaties Metabolic Reprogramming to Protect Hepatocytes from Lipotoxic Damage. Journal of Lipid Research 2022. [DOI: 10.1016/j.jlr.2022.100238] [Reference Citation Analysis]
2 Chen J, Mei Z, Wang Y, Chen Y, Liu Q. Causal effect of non-alcoholic fatty liver disease on atrial fibrillation. Eur J Intern Med 2022:S0953-6205(22)00256-4. [PMID: 35850912 DOI: 10.1016/j.ejim.2022.07.007] [Reference Citation Analysis]
3 Weinstein G, O'Donnell A, Davis-Plourde K, Zelber-Sagi S, Ghosh S, DeCarli CS, Thibault EG, Sperling RA, Johnson KA, Beiser AS, Seshadri S. Non-Alcoholic Fatty Liver Disease, Liver Fibrosis, and Regional Amyloid-β and Tau Pathology in Middle-Aged Adults: The Framingham Study. J Alzheimers Dis 2022. [PMID: 35213373 DOI: 10.3233/JAD-215409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Tan EX, Lee JW, Jumat NH, Chan WK, Treeprasertsuk S, Goh GB, Fan JG, Song MJ, Charatcharoenwitthaya P, Duseja A, Imajo K, Nakajima A, Seki Y, Kasama K, Kakizaki S, Lesmana LA, Zheng KI, Zheng MH, Koh CJ, Ho KY, Goh KL, Wong VW, Dan YY. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study. Metabolism 2021;126:154911. [PMID: 34648769 DOI: 10.1016/j.metabol.2021.154911] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Chan WK, Wong VW. Meaning of non-overlapping patients between the MAFLD and NAFLD definitions. Liver Int 2022;42:271-3. [PMID: 35092337 DOI: 10.1111/liv.15142] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Deng KQ, Huang X, Lei F, Zhang XJ, Zhang P, She ZG, Cai J, Ji YX, Li H. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. Am J Physiol Cell Physiol 2022. [PMID: 35759443 DOI: 10.1152/ajpcell.00123.2022] [Reference Citation Analysis]
7 Mantovani A, Byrne CD, Targher G. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(21)00261-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
8 Zhuge A, Li S, Lou P, Wu W, Wang K, Yuan Y, Xia J, Li B, Li L. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice. Microbiol Spectr 2022;:e0004722. [PMID: 35647690 DOI: 10.1128/spectrum.00047-22] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Duan X, Lv J, Jiang H, Zheng K, Chen Y, Zhao E. Inflammatory Cytokines, Adipocytokines, and Th17/Treg Balance in Patients with Nonalcoholic Fatty Liver Disease following Administration of Dahuang Zhechong Pills. Genetics Research 2022;2022:1-5. [DOI: 10.1155/2022/8560831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lin YP, Lin SH, Wang CC, Lin CC, Chen DW, Chuang CH, Huang PY, Hung CH, Yang SY, Cho WR, Chen YS, Tsai MC. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection. J Pers Med 2021;11:684. [PMID: 34442328 DOI: 10.3390/jpm11080684] [Reference Citation Analysis]
11 Fridén M, Rosqvist F, Ahlström H, Niessen HG, Schultheis C, Hockings P, Hulthe J, Gummesson A, Wanders A, Rorsman F, Risérus U, Vessby J. Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease. Front Med (Lausanne) 2021;8:814951. [PMID: 35083257 DOI: 10.3389/fmed.2021.814951] [Reference Citation Analysis]
12 Wang Q, Zhou D, Wang M, Zhu M, Chen P, Li H, Lu M, Zhang X, Shen X, Liu T, Chen L. A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population. Front Med 2022;9:900794. [DOI: 10.3389/fmed.2022.900794] [Reference Citation Analysis]
13 Portincasa P, Bonfrate L, Khalil M, Angelis MD, Calabrese FM, D’amato M, Wang DQ, Di Ciaula A. Intestinal Barrier and Permeability in Health, Obesity and NAFLD. Biomedicines 2022;10:83. [DOI: 10.3390/biomedicines10010083] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
14 Ni Y, Zhuge F, Ni L, Nagata N, Yamashita T, Mukaida N, Kaneko S, Ota T, Nagashimada M. CX3CL1/CX3CR1 interaction protects against lipotoxicity-induced nonalcoholic steatohepatitis by regulating macrophage migration and M1/M2 status. Metabolism 2022;:155272. [PMID: 35914622 DOI: 10.1016/j.metabol.2022.155272] [Reference Citation Analysis]
15 Mahlapuu M, Caputo M, Xia Y, Cansby E. GCKIII kinases in lipotoxicity: Roles in NAFLD and beyond. Hepatol Commun 2022. [PMID: 35641240 DOI: 10.1002/hep4.2013] [Reference Citation Analysis]
16 Delik A, Dinçer S, Ülger Y, Akkız H, Karaoğullarından Ü. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease. Gene 2022;833:146587. [PMID: 35598686 DOI: 10.1016/j.gene.2022.146587] [Reference Citation Analysis]
17 Chen X, Lu Y, Shi X, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. Front Oncol 2022;12:864106. [DOI: 10.3389/fonc.2022.864106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tripathi M, Singh BK, Zhou J, Tikno K, Widjaja A, Sandireddy R, Arul K, Ghani SABA, Bee GGB, Wong KA, Pei HJ, Shekeran SG, Sinha RA, Singh MK, Cook SA, Suzuki A, Lim TR, Cheah CC, Wang J, Xiao RP, Zhang X, Hoe Chow PK, Yen PM. Vitamin B12 and folate decrease inflammation and fibrosis in NASH by preventing Syntaxin 17 homocysteinylation. J Hepatol 2022:S0168-8278(22)02932-4. [PMID: 35820507 DOI: 10.1016/j.jhep.2022.06.033] [Reference Citation Analysis]
19 Abohashem S, Blankstein R. Hepatosteatosis and Atherosclerotic Disease: Disentangling the Overlap. Radiol Cardiothorac Imaging 2022;4:e220083. [PMID: 35506133 DOI: 10.1148/ryct.220083] [Reference Citation Analysis]
20 Ng CH, Lin SY, Chin YH, Lee MH, Syn N, Goh XL, Koh JH, Quek J, Hao Tan DJ, Mok SF, Tan E, Dan YY, Chew N, Khoo CM, Siddiqui MS, Muthiah M. Antidiabetic Medications for Type 2 Diabetics with Nonalcoholic Fatty Liver Disease: Evidence From a Network Meta-Analysis of Randomized Controlled Trials. Endocr Pract 2021:S1530-891X(21)01244-1. [PMID: 34606980 DOI: 10.1016/j.eprac.2021.09.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
21 Song Q, Liu H, Zhang Y, Qiao C, Ge S. Lipidomics Revealed Alteration of the Sphingolipid Metabolism in the Liver of Nonalcoholic Steatohepatitis Mice Treated with Scoparone. ACS Omega 2022;7:14121-7. [PMID: 35559132 DOI: 10.1021/acsomega.2c00693] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Liao C, Huang P, Chien H, Lin T, Yeh C, Lin K. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease. Biomedicines 2022;10:1232. [DOI: 10.3390/biomedicines10061232] [Reference Citation Analysis]
23 Panchal SK, John OD, Mathai ML, Brown L. Anthocyanins in Chronic Diseases: The Power of Purple. Nutrients 2022;14:2161. [PMID: 35631301 DOI: 10.3390/nu14102161] [Reference Citation Analysis]
24 Talens M, Tumas N, Lazarus JV, Benach J, Pericàs JM. What Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review. J Clin Med 2021;10:5019. [PMID: 34768539 DOI: 10.3390/jcm10215019] [Reference Citation Analysis]
25 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Ji Y, Liang Y, Mak JC, Ip MS. Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.04.006] [Reference Citation Analysis]
27 Moraes KCM, Montagne J. Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases. Front Physiol 2021;12:728407. [PMID: 34603083 DOI: 10.3389/fphys.2021.728407] [Reference Citation Analysis]
28 Quek SXZ, Tan EXX, Ren YP, Muthiah M, Loo EXL, Tham EH, Siah KTH. Factors early in life associated with hepatic steatosis. World J Hepatol 2022; 14(6): 1235-1247 [DOI: 10.4254/wjh.v14.i6.1235] [Reference Citation Analysis]
29 Du F, Sun H, Sun F, Yang S, Tan H, Li X, Chai Y, Jiang Q, Han D. Knockdown of TANK-Binding Kinase 1 Enhances the Sensitivity of Hepatocellular Carcinoma Cells to Molecular-Targeted Drugs. Front Pharmacol 2022;13:924523. [DOI: 10.3389/fphar.2022.924523] [Reference Citation Analysis]
30 Li W, Liu J, Cai J, Zhang XJ, Zhang P, She ZG, Chen S, Li H. NAFLD as a continuous driver in the whole spectrum of vascular disease. J Mol Cell Cardiol 2021;163:118-32. [PMID: 34737121 DOI: 10.1016/j.yjmcc.2021.10.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Rajak S, Gupta P, Anjum B, Raza S, Tewari A, Ghosh S, Tripathi M, Singh BK, Sinha RA. Role of AKR1B10 and AKR1B8 in the pathogenesis of non-alcoholic steatohepatitis (NASH) in mouse. Biochim Biophys Acta Mol Basis Dis 2021;:166319. [PMID: 34954342 DOI: 10.1016/j.bbadis.2021.166319] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xia Y, Caputo M, Cansby E, Anand SK, Sütt S, Henricsson M, Porosk R, Marschall HU, Blüher M, Mahlapuu M. STE20-type kinase TAOK3 regulates hepatic lipid partitioning. Mol Metab 2021;54:101353. [PMID: 34634521 DOI: 10.1016/j.molmet.2021.101353] [Reference Citation Analysis]
33 Hui Lim GE, Tang A, Ng CH, Chin YH, Lim WH, Hao Tan DJ, Yong JN, Xiao J, Wen-Min Lee C, Chan M, Chew NW, Xuan Tan EX, Siddiqui MS, Huang D, Noureddin M, Sanyal AJ, Muthiah MD. An Observational Data Meta-Analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01276-3. [PMID: 34871813 DOI: 10.1016/j.cgh.2021.11.038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
34 Qiu X, Gao F, Wang K, Zhang Z, Shao C, Xu X. Aspirin in hepatocellular carcinoma: Is it an out-of-date or promising treatment? iLIVER 2022;1:55-64. [DOI: 10.1016/j.iliver.2022.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Farooq M, Hameed H, Dimanche-Boitrel MT, Piquet-Pellorce C, Samson M, Le Seyec J. Switching to Regular Diet Partially Resolves Liver Fibrosis Induced by High-Fat, High-Cholesterol Diet in Mice. Nutrients 2022;14:386. [PMID: 35057565 DOI: 10.3390/nu14020386] [Reference Citation Analysis]
36 Liu Z, Suo C, Fan H, Zhang T, Jin L, Chen X. Dissecting causal relationships between nonalcoholic fatty liver disease proxied by chronically elevated alanine transaminase levels and 34 extrahepatic diseases. Metabolism 2022;:155270. [PMID: 35914620 DOI: 10.1016/j.metabol.2022.155270] [Reference Citation Analysis]
37 Policarpo S, Machado M, Barreira D, Cortez-pinto H. NAFLD Nutritional Management: Results from a Multidisciplinary Approach. GE Port J Gastroenterol. [DOI: 10.1159/000519932] [Reference Citation Analysis]
38 Crafa A, Condorelli RA, Cannarella R, Aversa A, Calogero AE, La Vignera S. Physical Examination for Endocrine Diseases: Does It Still Play a Role? J Clin Med 2022;11:2598. [PMID: 35566722 DOI: 10.3390/jcm11092598] [Reference Citation Analysis]
39 Patoulias D. Serum Resistin as a Biomarker in Nonalcoholic Fatty Liver Disease: Is This a Road to be Taken? J Clin Transl Hepatol 2021;9:454-5. [PMID: 34447672 DOI: 10.14218/JCTH.2021.00236] [Reference Citation Analysis]
40 Alon L, Corica B, Raparelli V, Cangemi R, Basili S, Proietti M, Romiti GF. Risk of cardiovascular events in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Prev Cardiol 2021:zwab212. [PMID: 34939092 DOI: 10.1093/eurjpc/zwab212] [Reference Citation Analysis]
41 Vachher M, Bansal S, Kumar B, Yadav S, Arora T, Wali NM, Burman A. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. J Cell Biochem 2022. [PMID: 35818831 DOI: 10.1002/jcb.30252] [Reference Citation Analysis]
42 Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Reference Citation Analysis]
43 Wei J, Tian J, Tang C, Fang X, Miao R, Wu H, Wang X, Tong X. The Influence of Different Types of Diabetes on Vascular Complications. J Diabetes Res 2022;2022:3448618. [PMID: 35242879 DOI: 10.1155/2022/3448618] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Luo T, Jiang S, Zhou B, Song Q, Du J, Liu P, Wang X, Song H, Shao C. Protective Effect of Isoorientin on Oleic Acid-Induced Oxidative Damage and Steatosis in Rat Liver Cells. Front Pharmacol 2022;13:818159. [DOI: 10.3389/fphar.2022.818159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ratziu V, Anstee QM, Wong VW, Schattenberg JM, Bugianesi E, Augustin S, Gheorghe L, Zambon V, Reau N. An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project. Hepatology 2022. [PMID: 35363906 DOI: 10.1002/hep.32500] [Reference Citation Analysis]
46 Tomah S, Hamdy O, Abuelmagd MM, Hassan AH, Alkhouri N, Al-Badri MR, Gardner H, Eldib AH, Eid EA. Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. BMJ Open Gastroenterol 2021;8:e000780. [PMID: 34610926 DOI: 10.1136/bmjgast-2021-000780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Zeng S, Chen Y, Wei C, Tan L, Li C, Zhang Y, Xu F, Zhu K, Wu G, Cao J. Protective effects of polysaccharide from Artocarpus heterophyllus Lam. (jackfruit) pulp on non-alcoholic fatty liver disease in high-fat diet rats via PPAR and AMPK signaling pathways. Journal of Functional Foods 2022;95:105195. [DOI: 10.1016/j.jff.2022.105195] [Reference Citation Analysis]
48 Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, Luo M. Association of Inflammatory Cytokines With Non-Alcoholic Fatty Liver Disease. Front Immunol 2022;13:880298. [DOI: 10.3389/fimmu.2022.880298] [Reference Citation Analysis]
49 He X, Sun Z, Ma K, Mei Y. [1-deoxynojirimycin alleviates liver fibrosis induced by type 2 diabetes in mice]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:1342-9. [PMID: 34658348 DOI: 10.12122/j.issn.1673-4254.2021.09.08] [Reference Citation Analysis]
50 Tang Y, Chen X, Chen Q, Xiao J, Mi J, Liu Q, You Y, Chen Y, Ling W. Association of serum methionine metabolites with non-alcoholic fatty liver disease: a cross-sectional study. Nutr Metab (Lond) 2022;19:21. [PMID: 35303918 DOI: 10.1186/s12986-022-00647-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Sun Q, Xin X, An Z, Hu Y, Feng Q. Therapeutic Potential of Natural Plants Against Non-Alcoholic Fatty Liver Disease: Targeting the Interplay Between Gut Microbiota and Bile Acids. Front Cell Infect Microbiol 2022;12:854879. [DOI: 10.3389/fcimb.2022.854879] [Reference Citation Analysis]
52 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]
53 Corey KE, Memel ZN. Bariatric Surgery as a Strategy for Improving Outcomes in Nonalcoholic Steatohepatitis. JAMA 2021;326:2015-7. [PMID: 34762134 DOI: 10.1001/jama.2021.17451] [Reference Citation Analysis]
54 Lin H, Wong VW. Is lean non-alcoholic fatty liver disease a distinct entity? Hepatol Int 2022. [PMID: 35325373 DOI: 10.1007/s12072-022-10324-9] [Reference Citation Analysis]
55 Lemmer P, Manka P, Best J, Kahraman A, Kälsch J, Vilchez-Vargas R, Link A, Chiang H, Gerken G, Canbay A, Bechmann LP, Sydor S. Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease. J Clin Med 2022;11:890. [PMID: 35160340 DOI: 10.3390/jcm11030890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
56 Martínez-Montoro JI, Cornejo-Pareja I, Gómez-Pérez AM, Tinahones FJ. Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:4077. [PMID: 34836332 DOI: 10.3390/nu13114077] [Reference Citation Analysis]
57 Luo Q, Wei R, Cai Y, Zhao Q, Liu Y, Liu WJ. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. Front Med 2022;9:793203. [DOI: 10.3389/fmed.2022.793203] [Reference Citation Analysis]
58 Doycheva I, Ehrmann DA. Nonalcoholic fatty liver disease and obstructive sleep apnea in women with polycystic ovary syndrome. Fertil Steril 2022;117:897-911. [PMID: 35512974 DOI: 10.1016/j.fertnstert.2022.03.020] [Reference Citation Analysis]
59 Chan TT, Tse YK, Lui RN, Wong GL, Chim AM, Kong AP, Woo J, Yeung DK, Abrigo JM, Chu WC, Wong VW, Tang RS. Fatty Pancreas Is Independently Associated With Subsequent Diabetes Mellitus Development: A 10-Year Prospective Cohort Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01041-7. [PMID: 34571257 DOI: 10.1016/j.cgh.2021.09.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
60 Xia J, Jin G, Hua Q, Cui S, Li J. Nomogram for Quantitatively Estimating the Risk of Fibrosis Progression in Type 2 Diabetic Patients With Nonalcoholic Fatty Liver Disease: A Pilot Study. Front Endocrinol 2022;13:917304. [DOI: 10.3389/fendo.2022.917304] [Reference Citation Analysis]
61 Yuan G, Xie F, Song Y, Li Q, Li R, Hu X, Zang M, Cheng X, Lu G, Huang J, Fan W, Rong X, Sun J, Chen J. Hepatic Tumor Stiffness Measured by Shear Wave Elastography Is Prognostic for HCC Progression Following Treatment With Anti-PD-1 Antibodies Plus Lenvatinib: A Retrospective Analysis of Two Independent Cohorts. Front Immunol 2022;13:868809. [PMID: 35757765 DOI: 10.3389/fimmu.2022.868809] [Reference Citation Analysis]
62 Wen H, Deng H, Yang L, Li L, Lin J, Zheng P, Ji G; Cochrane Hepato-Biliary Group. Vitamin E for people with non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015033] [Reference Citation Analysis]
63 Wang Q, Zhou H, Bu Q, Wei S, Li L, Zhou J, Zhou S, Su W, Liu M, Liu Z, Wang M, Lu L. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Pal SC, Eslam M, Mendez-Sanchez N. Detangling the interrelations between MAFLD, insulin resistance, and key hormones. Hormones (Athens) 2022. [PMID: 35921046 DOI: 10.1007/s42000-022-00391-w] [Reference Citation Analysis]
65 Wang Q, Zhu M, Li H, Chen P, Wang M, Gu L, Zhang X, Chen L. Hyperferritinemia Correlates to Metabolic Dysregulation and Steatosis in Chinese Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients. Diabetes Metab Syndr Obes 2022;15:1543-52. [PMID: 35607608 DOI: 10.2147/DMSO.S361187] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Sharma A, Virmani T, Sharma A, Chhabra V, Kumar G, Pathak K, Alhalmi A. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes Metab Syndr Obes 2022;15:1845-64. [PMID: 35733643 DOI: 10.2147/DMSO.S369712] [Reference Citation Analysis]
67 Guan C, Fu S, Zhen D, Yang K, An J, Wang Y, Ma C, Jiang N, Zhao N, Liu J, Yang F, Tang X, Sasso FC. Metabolic (Dysfunction)-Associated Fatty Liver Disease in Chinese Patients with Type 2 Diabetes from a Subcenter of the National Metabolic Management Center. Journal of Diabetes Research 2022;2022:1-9. [DOI: 10.1155/2022/8429847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Yang YY, Xie L, Zhang NP, Zhou D, Liu TT, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1180-90. [PMID: 35190696 DOI: 10.1038/s41401-022-00860-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
69 Bathish B, Robertson H, Dillon JF, Dinkova-Kostova AT, Hayes JD. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2. Free Radic Biol Med 2022;188:221-61. [PMID: 35728768 DOI: 10.1016/j.freeradbiomed.2022.06.226] [Reference Citation Analysis]
70 Guan X, Chen Y, Xu H. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. European Journal of Radiology 2022;154:110450. [DOI: 10.1016/j.ejrad.2022.110450] [Reference Citation Analysis]
71 Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, Arrese M, Fracanzani AL, Ben Bashat D, Lackner K, Gorfine T, Kadosh S, Oren R, Halperin M, Hayardeny L, Loomba R, Friedman S, Sanyal AJ; ARREST investigator study group. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med 2021;27:1825-35. [PMID: 34621052 DOI: 10.1038/s41591-021-01495-3] [Reference Citation Analysis]
72 Zhu W, Hong Y, Li Y, Li Y, Zhong J, He X, Zheng N, Sheng L, Li H. Microbial and Transcriptomic Profiling Reveals Diet-Related Alterations of Metabolism in Metabolic Disordered Mice. Front Nutr 2022;9:923377. [DOI: 10.3389/fnut.2022.923377] [Reference Citation Analysis]
73 Zhou H, Zeng X, Xue Y, Wang X, Liu S, Zhu Z, Luo Z, Ma Z, Zhang H, Zhan Q, Bai Y, Huang X, Zeng Q, Ren H, Xu D. Visit-to-Visit Fasting Glucose Variability in Young Adulthood and Nonalcoholic Fatty Liver Disease in Middle Age. J Clin Endocrinol Metab 2022;107:e2301-8. [PMID: 35244697 DOI: 10.1210/clinem/dgac122] [Reference Citation Analysis]
74 Perez-Diaz-Del-Campo N, Martínez-Urbistondo D, Bugianesi E, Martínez JA. Diagnostic scores and scales for appraising Nonalcoholic fatty liver disease and omics perspective for precision medicine. Curr Opin Clin Nutr Metab Care 2022. [PMID: 35788123 DOI: 10.1097/MCO.0000000000000849] [Reference Citation Analysis]
75 Xie J, Xu L, Xu C. Letter: skipping breakfast is associated with an increased long-term cardiovascular mortality in metabolic dysfunction-associated fatty liver disease (MAFLD) but not in MAFLD-free individuals. Authors' reply. Aliment Pharmacol Ther 2022;55:1067-8. [PMID: 35362128 DOI: 10.1111/apt.16876] [Reference Citation Analysis]
76 Martin A, Lang S, Goeser T, Demir M, Steffen HM, Kasper P. Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease. Curr Atheroscler Rep 2022. [PMID: 35507279 DOI: 10.1007/s11883-022-01028-4] [Reference Citation Analysis]
77 Zhang N, Wu Y, Zhong W, Xia G, Xia H, Wang L, Wei X, Li Y, Shang H, He H, Lin S. Multiple anti-non-alcoholic steatohepatitis (NASH) efficacies of isopropylidenyl anemosapogenin via farnesoid X receptor activation and TFEB-mediated autophagy. Phytomedicine 2022;102:154148. [DOI: 10.1016/j.phymed.2022.154148] [Reference Citation Analysis]
78 Liou C, Wu S, Shen S, Chen L, Chen Y, Huang W. Acacetin Protects against Non-Alcoholic Fatty Liver Disease by Regulating Lipid Accumulation and Inflammation in Mice. IJMS 2022;23:4687. [DOI: 10.3390/ijms23094687] [Reference Citation Analysis]
79 Chao Y, Wu P, Huang J, Chiu Y, Lee J, Chen S, Chang J, Hwang S, Chen H. Hepatic Steatosis Is Associated with High White Blood Cell and Platelet Counts. Biomedicines 2022;10:892. [DOI: 10.3390/biomedicines10040892] [Reference Citation Analysis]
80 Qayed E, Migdal AL, Jagannathan R, Miller LS, Pasquel FJ. Characteristics and Outcomes of Black and White Patients Hospitalized With Nonalcoholic Steatohepatitis: A Nationwide Analysis. J Clin Gastroenterol 2022. [PMID: 35357331 DOI: 10.1097/MCG.0000000000001698] [Reference Citation Analysis]
81 Aminian A, Al-Kurd A, Wilson R, Bena J, Fayazzadeh H, Singh T, Albaugh VL, Shariff FU, Rodriguez NA, Jin J, Brethauer SA, Dasarathy S, Alkhouri N, Schauer PR, McCullough AJ, Nissen SE. Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic Steatohepatitis. JAMA 2021;326:2031-42. [PMID: 34762106 DOI: 10.1001/jama.2021.19569] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
82 Dong Y, Wang WP, Lee WJ, Meloni MF, Clevert DA, Chammas MC, Tannapfel A, Forgione A, Piscaglia F, Dietrich CF. Contrast-Enhanced Ultrasound Features of Histopathologically Proven Hepatocellular Carcinoma in the Non-cirrhotic Liver: A Multicenter Study. Ultrasound Med Biol 2022:S0301-5629(22)00393-3. [PMID: 35710501 DOI: 10.1016/j.ultrasmedbio.2022.05.005] [Reference Citation Analysis]
83 Mao D, Xu M, Jiang Q, Sun H, Sun F, Yang R, Chai Y, Li X, Li B, Li Y. A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma. Front Pharmacol 2022;13:951831. [DOI: 10.3389/fphar.2022.951831] [Reference Citation Analysis]
84 Li L, Wang H, Yao Y, Cao J, Jiang Z, Yan W, Chu X, Li Q, Lu M, Ma H. The sex steroid precursor dehydroepiandrosterone prevents nonalcoholic steatohepatitis by activating the AMPK pathway mediated by GPR30. Redox Biol 2021;48:102187. [PMID: 34781165 DOI: 10.1016/j.redox.2021.102187] [Reference Citation Analysis]
85 Perdomo CM, Gómez-Ambrosi J, Becerril S, Valentí V, Moncada R, Fernández-Sáez EM, Méndez-Giménez L, Ezquerro S, Catalán V, Silva C, Escalada J, Frühbeck G, Rodríguez A. Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity. Int J Mol Sci 2021;22:12945. [PMID: 34884755 DOI: 10.3390/ijms222312945] [Reference Citation Analysis]
86 Wong GL, Wong VW. Targeting an energy sensor to prevent energy excess in the liver. Lancet Gastroenterol Hepatol 2021;6:876-7. [PMID: 34560016 DOI: 10.1016/S2468-1253(21)00307-1] [Reference Citation Analysis]
87 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]
88 Strnad P, Mandorfer M, Choudhury G, Griffiths W, Trautwein C, Loomba R, Schluep T, Chang T, Yi M, Given BD, Hamilton JC, San Martin J, Teckman JH. Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency. N Engl J Med 2022. [PMID: 35748699 DOI: 10.1056/NEJMoa2205416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Nagata N, Chen G, Xu L, Ando H. An Update on the Chemokine System in the Development of NAFLD. Medicina 2022;58:761. [DOI: 10.3390/medicina58060761] [Reference Citation Analysis]
90 Paternostro R, Trauner M. Current treatment of non-alcoholic fatty liver disease. J Intern Med 2022. [PMID: 35796150 DOI: 10.1111/joim.13531] [Reference Citation Analysis]
91 Phillips MC. Metabolic Strategies in Healthcare: A New Era. Aging Dis 2022;13:655-72. [PMID: 35656107 DOI: 10.14336/AD.2021.1018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
92 Cao YJ, Li HZ, Zhao J, Sun YM, Jin XW, Lv SQ, Luo JY, Fang XX, Wen WB, Liao JB. Mechanical Study of Jian-Gan-Xiao-Zhi Decoction on Nonalcoholic Fatty Liver Disease Based on Integrated Network Pharmacology and Untargeted Metabolomics. Evid Based Complement Alternat Med 2022;2022:2264394. [PMID: 35845577 DOI: 10.1155/2022/2264394] [Reference Citation Analysis]
93 Kuang M, Lu S, Xie Q, Peng N, He S, Yu C, Qiu J, Sheng G, Zou Y. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population. BMC Gastroenterol 2022;22:311. [PMID: 35752753 DOI: 10.1186/s12876-022-02393-9] [Reference Citation Analysis]
94 Gusev E, Zhuravleva Y. Inflammation: A New Look at an Old Problem. Int J Mol Sci 2022;23:4596. [PMID: 35562986 DOI: 10.3390/ijms23094596] [Reference Citation Analysis]
95 Zhou Y, Chai X, Guo T, Pu Y, Zeng M, Zhong A, Yang G, Cai J. A Prediction Model of the Incidence of Nonalcoholic Fatty Liver Disease With Visceral Fatty Obesity: A General Population-Based Study. Front Public Health 2022;10:895045. [DOI: 10.3389/fpubh.2022.895045] [Reference Citation Analysis]
96 Pan XY, Liu WY, Zhu PW, Li G, Tang LJ, Gao F, Huang OY, Yuan HY, Targher G, Byrne CD, Wang XD, Zheng MH. Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. Hepatol Int 2022. [PMID: 35829867 DOI: 10.1007/s12072-022-10384-x] [Reference Citation Analysis]
97 Du W, Wang L. The Crosstalk Between Liver Sinusoidal Endothelial Cells and Hepatic Microenvironment in NASH Related Liver Fibrosis. Front Immunol 2022;13:936196. [DOI: 10.3389/fimmu.2022.936196] [Reference Citation Analysis]
98 Yip TC, Wong VW, Wong GL. Alanine Aminotransferase Level: The Road to Normal in 2021. Hepatol Commun 2021;5:1807-9. [PMID: 34719129 DOI: 10.1002/hep4.1788] [Reference Citation Analysis]
99 Shen H, Yu H, Li QY, Wei YT, Fu J, Dong H, Cao D, Guo LN, Chen L, Yang Y, Xu Y, Wu MC, Wang HY, Chen Y. Hepatocyte-derived VEGFA accelerates the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via activating hepatic stellate cells. Acta Pharmacol Sin 2022. [PMID: 35508720 DOI: 10.1038/s41401-022-00907-5] [Reference Citation Analysis]
100 Mikkelsen ACD, Kjærgaard K, Mookerjee RP, Vilstrup H, Wegener G, Bay-Richter C, Thomsen KL. Non-alcoholic Fatty Liver Disease: Also a Disease of the Brain? A Systematic Review of the Preclinical Evidence. Neurochem Res 2022. [PMID: 35230646 DOI: 10.1007/s11064-022-03551-x] [Reference Citation Analysis]
101 Bardach C, Morski L, Mascherbauer K, Donà C, Koschutnik M, Halavina K, Nitsche C, Beitzke D, Loewe C, Waldmann E, Trauner M, Mascherbauer J, Hengstenberg C, Kammerlander A. Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. J Clin Med 2022;11:2863. [PMID: 35628989 DOI: 10.3390/jcm11102863] [Reference Citation Analysis]
102 Zhang Y, Liu X, Zhang H, Wang X. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Endocrinol 2022;13:836455. [DOI: 10.3389/fendo.2022.836455] [Reference Citation Analysis]
103 Baffy G. An engineered mayhem: YAP/TAZ mechanosignaling and hepatocarcinogenesis in NAFLD. Exploration of Medicine. [DOI: 10.37349/emed.2021.00048] [Reference Citation Analysis]
104 López-gonzález ÁA, Altisench Jané B, Masmiquel Comas L, Arroyo Bote S, González San Miguel HM, Ramírez Manent JI. Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study. Nutrients 2022;14:2795. [DOI: 10.3390/nu14142795] [Reference Citation Analysis]
105 Lin J, Li H, Wan Q. A Cross-Sectional Study of the Correlation Between the Atherogenic Index of Plasma and Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes. DMSO 2022;Volume 15:2227-34. [DOI: 10.2147/dmso.s375300] [Reference Citation Analysis]
106 Liu F, Wei L, Leow WQ, Liu S, Ren Y, Wang X, Li X, Rao H, Huang R, Wu N, Wee A, Zhao J. Developing a New qFIBS Model Assessing Histological Features in Pediatric Patients With Non-alcoholic Steatohepatitis. Front Med 2022;9:925357. [DOI: 10.3389/fmed.2022.925357] [Reference Citation Analysis]
107 Mantovani A, Dalbeni A. Recent Developments in NAFLD. Int J Mol Sci 2022;23:2882. [PMID: 35270024 DOI: 10.3390/ijms23052882] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
108 Zou Y, Li Q, Gao J, Pan J, Ma J, Chen L, Lin J, Mo Y, Zhang X, Liu P, Dai L. Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort. Front Cardiovasc Med 2022;9:884636. [DOI: 10.3389/fcvm.2022.884636] [Reference Citation Analysis]
109 Tarantino G, Citro V, Cataldi M. Findings from Studies Are Congruent with Obesity Having a Viral Origin, but What about Obesity-Related NAFLD? Viruses 2021;13:1285. [PMID: 34372491 DOI: 10.3390/v13071285] [Reference Citation Analysis]
110 Napoli R, Avogaro A, Formoso G, Piro S, Purrello F, Targher G, Consoli A. Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutr Metab Cardiovasc Dis 2021;31:3257-70. [PMID: 34627692 DOI: 10.1016/j.numecd.2021.08.039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Mantovani A, Targher G. Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic steatohepatitis: new insights from subcutaneous semaglutide. Hepatobiliary Surg Nutr 2021;10:518-21. [PMID: 34430533 DOI: 10.21037/hbsn-2021-13] [Reference Citation Analysis]